Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers

Annals of Neurology

Volumn 58, Issue 3, 2005, Pages 411-422

  Pramstaller, Peter P ^a,b,f,i   Schlossmacher, Michael G ^c,d   Jacques, Thomas S ^e   Scaravilli, Francesco ^e   Eskelson, Cordula ^f   Pepivani, Imelda ^c,d   Hedrich, Katja ^f   Adel, Susanna ^f   Gonzales McNeal, Melissa ^g   Hilker, Rüdiger ^h   Kramer, Patricia L ^g   Klein, Christine ^f  

^a Central Hospital   (Italy)

^b INSTITUTE FOR RENEWABLE ENERGY   (Italy)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF LÜBECK   (Germany)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ CENTRAL HOSPITAL OF BOLZANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PARKIN;

ADOLESCENT; ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; AUTOPSY; CELL INCLUSION; CELL LOSS; CELL SURVIVAL; CHILD; CLINICAL FEATURE; DRUG SENSITIVITY; DYSKINESIA; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; GLIOSIS; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; HUMAN TISSUE; LEWY BODY; LOCUS CERULEUS; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROPATHOLOGY; ONSET AGE; PARKIN GENE; PARKINSON DISEASE; PARKINSONISM; PEDIGREE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; SUBSTANTIA NIGRA; SURVIVAL RATE;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ALLELES; DEMOGRAPHY; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEURONS; PARKINSON DISEASE; PEDIGREE; POSTMORTEM CHANGES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SUBSTANTIA NIGRA; SURVIVAL ANALYSIS; UBIQUITIN-PROTEIN LIGASES;

EID: 24644462201     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20587     Document Type: Article

References (48)

1. Hedrich K, Eskelson C, Wilmot B, et al. Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord 2004;19:1146-1157.
2. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med 2000;342:1560-1567.
3. Kann M, Jacobs H, Mohrmann K, et al. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Ann Neurol 2002;51:621-625.
4. Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 2003;4:176-185.
5. Hedrich K, Kann M, Lanthaler AJ, et al. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum Mol Genet 2001;10:1649-1656.
6. Klein C, Pramstaller PP, Kis B, et al. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol 2000;48:65-71.
7. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001;50: 293-300.
8. Sasaki S, Shirata A, Yamane K, et al. Parkin-positive autosomal recessive juvenile parkinsonism with alpha-synuclein-positive inclusions. Neurology 2004;63:678-682.
9. Hedrich K, Marder K, Harris J, et al. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology 2002;58:1239-1246.
10. Hilker R, Klein C, Hedrich K, et al. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett 2002;323: 50-54.
11. West A, Periquet M, Lincoln S, et al. Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet 2002;114:584-591.
12. Foroud T, Uniacke SK, Liu L, et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 2003;60:796-801.
13. Hilker R, Klein C, Ghaemi M, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001;49:367-376.
14. Walter U, Klein C, Hilker R, et al. Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 2004;19: 1445-1449.
15. Gibb WR, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 1988;38:1402-1406.
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. 1967. Neurology 2001;57:S11-S26.
17. Fahn S, Elton RL, and Members of the UPDRS Development Committee. Recent developments in Parkinson's disease. In: Fahn S, Goldstein M, Calne DB, et al, eds. Recent developments in Parkinson's disease. Vol 2. Florham Park, NJ: MacMillan Healthcare Information, 1987:205-211.
18. Schlossmacher MG, Frosch MP, Gai WP, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 2002;160:1655-1667.
19. Schlossmacher MG, Shimura H. Parkinson's disease-assays for the ubiquitin ligase activity of neural parkin. In: Patterson C, Cyr DM, eds. Methods in molecular biology: ubiquitin-proteasome protocols. Totawa, NJ: Humana Press, 2005:315-369.
20. Pawlyk AC, Giasson BI, Sampathu DM, et al. Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem 2003;278:48120-48128.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
22. Jellinger KA, Mizuno Y. Parkinson's disease. In: Dickson DW, ed. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel, Switzerland: ISN Neuropath Press, 2003:159-186.
23. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
24. Bandopadhyay R, Kingsbury AE, Muqit MM, et al. Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition. Neurobiol Dis 2005; May 12 epub.
25. Hoehn MM. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992;10: 331-339.
26. Yamamura Y, Sobue I, Ando K, et al. Paralysis agitans of early onset with marked diurnal fluctuation of symptoms. Neurology 1973;23:239-244.
27. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
28. Jones AC, Yamamura Y, Almasy L, et al. Autosomal recessive juvenile parkinsonism maps to 6q25.2-q27 in four ethnic groups: detailed genetic mapping of the linked region. Am J Hum Genet 1998;63:80-87.
29. Mon H, Kondo T, Yokochi M, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998;51:890-892.
30. Hayashi S, Wakabayashi K, Ishikawa A, et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 2000;15:884-888.
31. van de Warrenburg BP, Lammens M, Lucking CB, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001;56:555-557.
32. Morales B, Martinez A, Gonzalo I, et al. Steele-Richardson-Olszewski syndrome in a patient with a single C212Y mutation in the parkin protein. Mov Disord 2002;17:1374-1380.
33. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
34. Chung KK, Zhang Y, Lim KL, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 2001; 7:1144-1150.
35. Zhang Y, Gao J, Chung KK, et al. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A 2000;97:13354-13359.
36. D'Agata V, Cavallaro S. Genomic portraits of the nervous system in health and disease. Neurochem Res 2004;29:1201-1212.
37. Lo Bianco C, Schneider BL, Bauer M, et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A 2004;101:17510-17515.
38. Cookson MR, Lockhart PJ, McLendon C, et al. RING finger 1 mutations in Parkin produce altered localization of the protein. Hum Mol Genet 2003;12:2957-2965.
39. Goldberg MS, Fleming SM, Palacino JJ, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003;278:43628-43635.
40. Palacino JJ, Sagi D, Goldberg MS, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004;279:18614-18622.
41. Chen L, Feany MB. alpha-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005;8:657-663.
42. Khan NL, Graham E, Critchley P, et al. Parkin disease: a phenotypic study of a large case series. Brain 2003;126: 1279-1292.
43. Oliveira SA, Scott WK, Martin ER, et al. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol 2003;53:624-629.
44. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:10-15.
45. Lincoln SJ, Maraganore DM, Lesnick TG, et al. Parkin variants in North American Parkinson's disease: cases and controls. Mov Disord 2003;18:1306-1311.
46. Pankratz N, Nichols WC, Uniacke SK, et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet 2003;12:2599-2608.
47. Broussolle E, Lucking CB, Ginovart N, et al. [18 F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations. Neurology 2000;55:877-879.
48. Khan NL, Brooks DJ, Pavese N, et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002;125:2248-2256.